ANTHEM BIOSCIENCES LTD Fair Value
ANTHEM · Healthcare · Current price ₹942
| Method | Fair value | Status |
|---|---|---|
| Residual income | ₹126 | 22% ROE fading to 12% over ~20 yrs, on ₹54 book |
| Relative P/E | ₹412 | EPS × 39.1 peer-median P/E |
| Graham floor | ₹113 | Conservative floor: √(22.5 × EPS × book value/share) |
| Analyst target | ₹905 | Street consensus 12-month target price |
Is ANTHEM BIOSCIENCES LTD undervalued?
DocStoX estimates the fair value of ANTHEM BIOSCIENCES LTD at ₹330 per share, versus the current market price of ₹942. That puts the stock about -65.0% above our fair-value estimate, which we read as "Avoid". Our confidence in this estimate is low.
How this fair value is calculated
This estimate blends 4 independent methods: Residual income (₹126), Relative P/E (₹412), Graham floor (₹113), Analyst target (₹905). We weight each by its reliability and skip any method whose inputs look untrustworthy — "no DCF beats a wrong DCF". This is the same deterministic engine that powers DocStoX stock pages; there is no guesswork or AI-generated number here.
Bear, base and bull scenarios
Our scenarios span ₹113 (bear) to ₹330 (base) to ₹905 (bull). A margin of safety means buying meaningfully below the base case — the wider the gap, the more room for error in the assumptions.
More on ANTHEM BIOSCIENCES LTD
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.